2025 ACR SLE Guideline Prioritizes Hydroxychloroquine and Glucocorticoid Minimization

The American College of Rheumatology reframes non-renal SLE management around universal hydroxychloroquine, aggressive glucocorticoid tapering, and earlier immunosuppressive escalation.

2025 ACR SLE GuidelineAmerican College of Rheumatologysystemic lupus erythematosushydroxychloroquineglucocorticoidsbiologic immunosuppressants Rheumatology / Immunology

Background Information

New guidelines unify SLE treatment strategies for better outcomes.

Systemic lupus erythematosus (SLE) significantly impacts morbidity and mortality; uniform guidelines enhance treatment efficacy. Consensus was reached on recommendations, including hydroxychloroquine use, short-term glucocorticoids, and early immunosuppressives. The guideline promotes evidence-based management for SLE, encouraging shared decision-making while recognizing individual patient needs. This guideline offers a unified approach to manage SLE, aiming to minimize disease activity and treatment toxicity.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, Son MBF, Werth VP, Aranow C, Barnado A, Broder A, Brunner HI, Chong BF, Chowdhary VR, Hersh AO, Izmirly PM, Jules M, Kalunian K, Kamen D, Rubinstein TB, Smith BJ, Smith NM, Thomas A, Timlin H, Wallace DJ, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Gomes LLA, Cuéllar-Gutiérrez MC, Iyer P, Johannemann AS, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Legge A, Liang KP, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Turner AS, Mustafa RA

Citation: Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.). 2026;78(7):1361-1386. doi:10.1002/art.43452

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →